Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Japan Lifeline CoFRA:L8B +1.39%84 Return-on-Tangible-Equity is 16.03% as of Mar. 2026, which is 2% above its 10-year median of 15.65. GuruFocus rates FRA:L8B with a GF Score™ of 84/100 and a GF Value™ of €8.11. Among 759 Medical Devices & Instruments companies, Japan Lifeline Co ranks better than 77.21% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Japan Lifeline Co's annualized net income for the quarter that ended in Mar. 2026 was €55.1 Mil. Japan Lifeline Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €343.9 Mil. Therefore, Japan Lifeline Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 16.03%.
The historical rank and industry rank for Japan Lifeline Co's Return-on-Tangible-Equity or its related term are showing as below:
FRA:L8B'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.93 Med: 15.65 Max: 29.71
Current: 15.6
During the past 13 years, Japan Lifeline Co's highest Return-on-Tangible-Equity was 29.71%. The lowest was 3.93%. And the median was 15.65%.
FRA:L8B's Return-on-Tangible-Equity is ranked better than 77.21% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs FRA:L8B: 15.60
Japan Lifeline Co (FRA:L8B) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Japan Lifeline Co Return-on-Tangible-Equity Related Terms
Japan Lifeline Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Japan Lifeline Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:L8B vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Japan Lifeline Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Lifeline Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Japan Lifeline Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Japan Lifeline Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 16.03% mean?
Japan Lifeline Co (FRA:L8B) has a Return-on-Tangible-Equity of 16.03% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Japan Lifeline Co and its competitors. This is near median its historical median of 15.65. Over the past decade, Japan Lifeline Co's Return-on-Tangible-Equity has ranged from 3.93 to 29.71. According to the industry distribution chart, Japan Lifeline Co ranks #173 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 22.8%.
Is Japan Lifeline Co's Return-on-Tangible-Equity too high?
Japan Lifeline Co's current Return-on-Tangible-Equity of 16.03% is near median its 10-year median of 15.65. Over the past 10 years, this metric has ranged from a low of 3.93 to a high of 29.71. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.04. Japan Lifeline Co's value of 16.03% is 296.8% above this industry median. Based on the distribution chart, Japan Lifeline Co ranks #173 out of 759 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Japan Lifeline Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Japan Lifeline Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Japan Lifeline Co ranks #173 out of 759 companies for Return-on-Tangible-Equity. This places Japan Lifeline Co in the top 23% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.04. Japan Lifeline Co's value of 16.03% is 296.8% above this benchmark. Historically, Japan Lifeline Co's own Return-on-Tangible-Equity has ranged from 3.93 to 29.71 over the past decade. While the company's 10-year median is 15.65 vs. the industry median of 4.04, Japan Lifeline Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Japan Lifeline Co's current Return-on-Tangible-Equity of 16.03% is 296.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Japan Lifeline Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Japan Lifeline Co's current Return-on-Tangible-Equity is 16.03%, which is near median its own 10-year median of 15.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Lifeline Co stock overvalued right now?
Japan Lifeline Co (FRA:L8B) has a current Return-on-Tangible-Equity of 16.03%. The stock's GF Value™ is €8.11, compared to a current price of €7.30 — trading 10% below its estimated fair value. The current Return-on-Tangible-Equity is 16.03%, which is near median its 10-year median of 15.65 and 296.8% above the Medical Devices & Instruments industry median of 4.04. Japan Lifeline Co's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Japan Lifeline Co (FRA:L8B), the current Return-on-Tangible-Equity is 16.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Lifeline Co (FRA:L8B) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Lifeline Co stock appears to be undervalued.
The current stock price of €7.30 is trading 10% below its estimated GF Value™ of €8.11.
Key valuation signals for FRA:L8B:
Return-on-Tangible-Equity: 16.03% (near median its 10-year median of 15.65)
GF Value™: €8.11 vs. price of €7.30 (10% below fair value)
Industry Position: 296.8% above the Medical Devices & Instruments median (#173 of 759)
No single metric tells the full story. See the FRA:L8B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Lifeline Co Ltd is a medical device company operating in Japan. It is engaged in the trading and manufacturing of medical devices specialized in the cardiovascular field. The company offers medical devices mainly for the treatment of cardiac and vascular diseases. It focuses on providing implantable devices to treat arrhythmias; disposable catheter devices with electrodes for diagnosis and treatment of arrhythmias; prosthetic devices to replace blood vessels and heart valves that lost their functions; and devices for intravascular treatment of cardiac infarction, arterial occlusions of the lower extremities and congenital cardiac diseases.
84GF Score
Get the complete analysis for FRA:L8B
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L8B has been successfully added to your 
